表紙
市場調査レポート

再発性慢性リンパ性白血病(CLL):世界の治験レビュー

Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 304739
出版日 ページ情報 英文 185 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
再発性慢性リンパ性白血病(CLL):世界の治験レビュー Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014
出版日: 2014年05月26日 ページ情報: 英文 185 Pages
概要

当レポートでは、再発性慢性リンパ性白血病(CLL)に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、治験における主要国、G7諸国およびE7(新興7カ国)における治験数および被験者採用の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報をまとめてお届けします。

目次

イントロダクション

  • 再発性慢性リンパ性白血病(CLL)
  • 当レポートの概要

各地域における治験状況

各国の治験件数と平均被験者数

  • アジア太平洋地域の上位5カ国における治験件数
  • 欧州上位5ヶ国における治験件数
  • 北米の主要国における治験件数
  • 中東およびアフリカの主要国における治験件数
  • 中南米の主要国における治験件数

G7諸国での治験件数:がんの治験件数に対する再発性慢性リンパ性白血病(CLL)の比率

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7(新興7カ国)における治験件数:がんの治験件数に対する再発性慢性リンパ性白血病(CLL)の比率

E7(新興7カ国)での治験件数:フェーズ(相)別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

エンドポイント達成状況別の治験件数

未達成の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

有望な薬剤

最新の治験情報

治験のプロファイル

  • 代表的企業の治験の概要
    • F.Hoffmann-La Roche Ltd.
    • Pharmacyclics, Inc.
    • GlaxoSmithKline plc
    • Celgene Corporation
    • AbbVie Inc.
    • Janssen Global Services, LLC
    • Sanofi
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
  • 代表的な研究機関・病院の治験の概要
    • National Cancer Institute
    • The University of Texas M. D. Anderson Cancer Center
    • Ohio State University Comprehensive Cancer Center
    • Massachusetts General Hospital
    • Eastern Cooperative Oncology Group
    • Fred Hutchinson Cancer Research Center
    • Roswell Park Cancer Institute
    • University of Kentucky
    • Beth Israel Deaconess Medical Center
    • Duke University

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2159CTIDB

GlobalData's clinical trial report, "Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014" provides data on the Relapsed Chronic Lymphocytic Leukemia (CLL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Relapsed Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Relapsed Chronic Lymphocytic Leukemia (CLL). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Relapsed Chronic Lymphocytic Leukemia (CLL)
    • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
    • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
    • Top Five Countries Contributing to Clinical Trials in Europe
    • Top Countries Contributing to Clinical Trials in North America
    • Top Countries Contributing to Clinical Trials in Middle East and Africa
    • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Relapsed Chronic Lymphocytic Leukemia (CLL)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Relapsed Chronic Lymphocytic Leukemia (CLL)
    • Dec 09, 2013: Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia
    • Dec 09, 2013: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol in CLL and MM Studies
    • Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL
    • Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Pharmacyclics, Inc.
      • Clinical Trial Overview of Pharmacyclics, Inc.
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Janssen Global Services, LLC
      • Clinical Trial Overview of Janssen Global Services, LLC
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Gilead Sciences, Inc.
      • Clinical Trial Overview of Gilead Sciences, Inc.
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • The University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
      • Ohio State University Comprehensive Cancer Center
      • Clinical Trial Overview of Ohio State University Comprehensive Cancer Center
      • Massachusetts General Hospital
      • Clinical Trial Overview of Massachusetts General Hospital
      • Eastern Cooperative Oncology Group
      • Clinical Trial Overview of Eastern Cooperative Oncology Group
      • Fred Hutchinson Cancer Research Center
      • Clinical Trial Overview of Fred Hutchinson Cancer Research Center
      • Roswell Park Cancer Institute
      • Clinical Trial Overview of Roswell Park Cancer Institute
      • University of Kentucky
      • Clinical Trial Overview of University of Kentucky
      • Beth Israel Deaconess Medical Center
      • Clinical Trial Overview of Beth Israel Deaconess Medical Center
      • Duke University
      • Clinical Trial Overview of Duke University
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Global Services, LLC, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ohio State University Comprehensive Cancer Center, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Kentucky, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Beth Israel Deaconess Medical Center, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014*

List of Figures

  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Relapsed Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top